LOXL1 and glioblastoma: At the mRNA level, Loxl1 expression was positively related to dendritic cells and negatively correlated with B cells and neutrophils (Fig. 6I), which implies that Loxl1 has promising potential for assessing the efficacy of GBM immunotherapy.